Following up a pioneering 07 proof-of-concept study, a University of Utah biochemist and colleagues have designed a promising new anti-HIV drug candidate, PIE12-trimer, that stops HIV from attacking human cells. Michael S. Kay, M.D., Ph.D., associate professor of biochemistry in the University of Utah university of treatments and senior author within of the analyze published Wednesday, Aug. 18, 2010, web based through the Journal of Virology, is raising funds to start pet security studies, adopted by human clinical trials in two to 3 years. Kay believes PIE12-trimer is ideally appropriate for use as being a genital microbicide (topically applied drug) to prevent HIV infection. His investigating group is primarily concentrated on preventing the spread of HIV in Africa, which has an believed two-thirds within of the world’s 33 million HIV patients based on the earth overall health Organization.

“We think that PIE12-trimer could provide a major new weapon in the arsenal against HIV/AIDS. considering of its ability to prevent the trojan from infecting new cells, PIE12-trimer has the potential to work as being a microbicide to prevent people from contracting HIV and as being a treatment for HIV infected people. HIV can develop resistance rapidly to existing drugs, so there is unquestionably in reality a constant may potentially need to develop new harmful drugs in hopes of remaining ahead within of the virus.” Kay said.

PIE12-trimer was constructed with a unique “resistance capacitor” that provides it with a powerful defense against the emergence of drug-resistant viruses.

Peptide harmful drugs have great therapeutic potential, but are commonly hampered by their quick degradation in the body. D-peptides are mirror-image versions of natural peptides that may not be ruined down, potentially biggest to higher potency and longevity in the body. regardless of these potential advantages, no D-peptides have however been developed.

PIE12-trimer consists of 3 D-peptides (PIE12) associated together that prevent a “pocket” on the region of HIV critical for HIV’s gaining entry into the cell. “Clinical trials will determine if PIE12-trimer is as useful in humans as it truly is in the lab,” Kay said.

Across the world, HIV usually requires place in several completely different strains and has the ability to mutate to resist harmful drugs aimed at stopping it. caused by the high conservation within of the wallet region across strains, PIE12-trimer worked against all major HIV strains worldwide, from Southeast Asia and South the states to the United says and Africa.

To aid advance toward human clinical trials, Kay and co-authors Brett D. Welch, Ph.D., and Debra M. Eckert, Ph.D., investigating assistant professor of biochemistry, formed a company, Kayak Biosciences, which is owned through the University of Utah investigating Foundation. If PIE12-trimer proves to be an useful and safe drug against HIV, the identical D-Peptide drug style and design rules is normally applied against other viruses, based on Kay. Approval within of the highly 1st D-peptide drug would also greatly stimulate development of other D-peptide drugs.

Source: University of Utah overall health Sciences